Towards safer thrombolytic therapy

被引:35
|
作者
Marder, VJ
Stewart, D
机构
[1] LA Orthopaed Hosp, Dept Vasc Med, Los Angeles, CA 90007 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Med, Hematol Med Oncol Div, Los Angeles, CA 90024 USA
关键词
D O I
10.1053/shem.2002.34088
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasminogen activators (PA) are unique agents that are currently applied as thrombolytic therapy to achieve rapid vascular reperfusion. Regimens of PA plus anticoagulants and antiplatelet drugs have attained a high degree of sophistication and predictable rates of positive clinical outcomes for acute myocardial infarction (MI), ischemic stroke, pulmonary embolism (PE), deep vein thrombosis (DVT), and thrombosed catheters. Included in the repertoire are newly approved mutants of tissue plasminogen activator (TPA), which have biochemical advantages that allow for bolus administration. Yet despite tremendous effort devoted to enormous trials to establish the clinical efficacy of these agents in acute MI, mortality results are not superior to those with native TPA or streptokinase (SK). Furthermore, all PAs have the potential for hemorrhagic complication, most critically intracranial hemorrhage (ICH), occurring in 0.9% of patients treated with native or mutant TPA. It is possible that a limit of clinical effectiveness has been reached, beyond which more potent PAs do not achieve greater benefit without a serious increase in risk of bleeding. A breakthrough is possible, however, if the risk of ICH could be avoided. One solution is the application of the direct-acting thrombolytic enzyme, plasmin. While intravenous plasmin is not effective when administered systemically, regional infusion to a thrombus induces local thrombolysis. Unlike the PAs, plasmin treatment should not cause hemorrhage from vascular trauma sites, as it is neutralized by antiplasmin in the blood. Animal studies are fully consistent with this approach, which offers potential for achieving a truly regional thrombolytic treatment. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:206 / 216
页数:11
相关论文
共 50 条
  • [1] TOWARDS IMPROVED THROMBOLYTIC THERAPY
    COLLEN, D
    LANCET, 1993, 342 (8862): : 34 - 36
  • [2] TOWARDS BETTER THROMBOLYTIC THERAPY
    COLLEN, D
    LIJNEN, HR
    GOLD, HK
    PROGRESS IN CARDIOVASCULAR DISEASES, 1991, 34 (02) : 101 - 112
  • [3] THROMBOLYTIC THERAPY - TOWARDS A DECREASING RISK OF HEMORRHAGE
    SIE, P
    NOUVELLE REVUE DE MEDECINE DE TOULOUSE, 1985, 3 (10): : 578 - 579
  • [4] Remote Controlled CARs: Towards a Safer Therapy for Leukemia
    June, Carl H.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (08) : 643 - 643
  • [5] Molecular Transport of a Magnetic Nanoparticle Swarm Towards Thrombolytic Therapy
    Manamanchaiyaporn, Laliphat
    Tang, Xiuzhen
    Zheng, Yuanyi
    Yan, Xiaohui
    IEEE ROBOTICS AND AUTOMATION LETTERS, 2021, 6 (03): : 5605 - 5612
  • [6] AZD6140 and bleeding: towards safer antiplatelet therapy?
    Siddique, A.
    Shantsila, E.
    Lip, G. Y. H.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (04) : 537 - 539
  • [7] THROMBOLYTIC THERAPY
    COLLEN, D
    LIJNEN, HR
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1991, 614 : 259 - 269
  • [8] THROMBOLYTIC THERAPY
    MCNICOL, GP
    PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1963, 56 (05): : 414 - 418
  • [9] THROMBOLYTIC THERAPY
    SHERRY, S
    FLETCHER, AP
    AMERICAN HEART JOURNAL, 1961, 61 (05) : 575 - &
  • [10] THROMBOLYTIC THERAPY
    FRATANTONI, JC
    AMERICAN HEART JOURNAL, 1977, 93 (03) : 271 - 273